Gene Editing Deal Broadens Vertex's CF Base, Doubles CRISPR's Cash

Vertex Pharmaceuticals made a big financial commitment to expand its cystic fibrosis portfolio beyond drugs for patients with specific genetic mutations to gene-editing therapies that may cure CF via a new partnership with CRISPR Therapeutics that more than doubles the startup firm's cash balance.